Anti-SPINK1 (hPSTI) Antibody
- Antibody to Serine protease inhibitor Kazal-type 1 (SPINK1; human pancreatic secretory trypsin inhibitor domain (hPSTI))
- Recognizes native hPSTI (soluble as well as hPSTI in the pSKAN phagemid pIII-hPSTI fusion protein)
- Monoclonal mouse IgG (clone R XXIII)
- Reports indicate a potential of SPINK1 as an extracellular therapeutic target in prostate cancer
The anti-SPINK1 (hPSTI) antibody was specifically developed for our pSKAN Phagemid Display System, but can also be useful in other applications related to the human pancreatic secretory trypsin inhibitor (hPSTI).
"About 10 percent of prostate cancer patients are SPINK1-positive and strategies to block SPINK1 signaling may have utility in this subset of patients. These studies should stimulate the development of antibody-based therapies against SPINK1 or targeting of EGFR in SPINK1-positive cancer patients," says study author Bushra Ateeq, a research fellow at the U-M Medical School.
PAGE of pSKAN phages presenting different hPSTI-pIII fusion proteins followed by Western blot with anti-pIII (Lane 1-5); M13K07 wild type phage as control (Lane M13). Two bands are visible with pSKAN phages: one for pIII and one for the larger hybrid protein hPSTI-pIII. In M13 wild type phages only one band is detected resulting from pIII.
- For shipping and storage information please click on Order#.